Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction | Zendy

Jessica L. Mega | Zendy; David A. Morrow | Zendy; Erika Östör | Zendy; Maria Dorobanţu | Zendy; Jie Qin | Zendy; Elliott M. Antman | Zendy; Eugene Braunwald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction

Author(s) -

Jessica L. Mega,

David A. Morrow,

Erika Östör,

Maria Dorobanţu,

Jie Qin,

Elliott M. Antman,

Eugene Braunwald

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.679548

Subject(s) - medicine , timi , myocardial infarction , thrombolysis , enoxaparin sodium , cardiology , fibrinolysis , antithrombotic , odds ratio , reperfusion therapy , mortality rate , fibrinolytic agent , heparin , low molecular weight heparin

The manifestations, complications, and outcomes of cardiovascular disease differ between women and men. The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research